Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 201–300 of 1,060

ACC/AHA/NHLBI clinical advisory on the use and safety of statins11When citing this document, the American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute would appreciate the following citation format: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568–73.22This document is available on the Web sites of the ACC (www.acc.org), the AHA (www.americanheart.org), and the NHLBI (www.nhlbi.nih.gov/guidelines/cholesterol).
Pasternak, R. C., Smith, S. C., Merz, C. N. B., Grundy, S. M., Cleeman, J. I., & Lenfant, C. J. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02030-2 · Cited by 507
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
Civeira, F. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.11.010 · Cited by 495
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy
Takemoto, M., Node, K., Nakagami, H., Liao, Y., Grimm, M. F., Takemoto, Y., Kitakaze, M., & Liao, J. K. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13350 · Cited by 485
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention
Patti, G., Pasceri, V., Colonna, G., Miglionico, M., Fischetti, D., Sardella, G., Montinaro, A., & Sciascio, G. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.025 · Cited by 483
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474
Obesity and Inflammation: Epidemiology, Risk Factors, and Markers of Inflammation
Rodríguez-Hernández, H., Simental‐Mendía, L. E., Ramírez, G. R., & Reyes-Romero, M. A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/678159 · Cited by 509
Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes
Heeschen, C., Hamm, C. W., Laufs, U., Snapinn, S. M., Böhm, M., & White, H. D. (2002) · Circulation · doi:10.1161/01.cir.0000012530.68333.c8 · Cited by 478
Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction
Stein, J. H., Klein, M. A., Bellehumeur, J. L., McBride, P. E., Wiebe, D. A., Otvos, J. D., & Sosman, J. M. (2001) · Circulation · doi:10.1161/01.cir.104.3.257 · Cited by 478
Prevalence of statin intolerance: a meta-analysis
Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac015 · Cited by 481
Statins: new American guidelines for prevention of cardiovascular disease
Ridker, P. M., & Cook, N. R. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62388-0 · Cited by 477
Statins for Improving Renal Outcomes
Sandhu, S., Wiebe, N., Fried, L. F., & Tonelli, M. A. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010012 · Cited by 475
Optimal low-density lipoprotein is 50 to 70 mg/dl
O’Keefe, J. H., Cordain, L., Harris, W. H., Moe, R. M., & Vogel, R. A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.046 · Cited by 483
Ezetimibe
Kosoglou, T., Statkevich, P., Johnson‐Levonas, A. O., Paolini, J. F., Bergman, A. J., & Alton, K. B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544050-00002 · Cited by 479
Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease
Sacks, F. M., & Katan, M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00987-1 · Cited by 477
Hydrophilicity/ lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
Hamelin, B. A. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01147-4 · Cited by 468
Cardiovascular Toxicities of Immunosuppressive Agents
Miller, L. W. (2002) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2002.20902.x · Cited by 470
Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention
Pasceri, V., Patti, G., Nusca, A., Pristipino, C., Richichi, G., & Sciascio, G. D. (2004) · Circulation · doi:10.1161/01.cir.0000137828.06205.87 · Cited by 466
2016 Chinese guidelines for the management of dyslipidemia in adults.
(2018) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2018.01.011 · Cited by 575
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species
Waßmann, S., Laufs, U., Bäumer, A. T., Müller, K., Ahlbory, K., Linz, W., Itter, G., Rösen, R., Böhm, M., & Nickenig, G. (2001) · Hypertension · doi:10.1161/01.hyp.37.6.1450 · Cited by 453
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2011) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 465
Isoprostanes: Potential Markers of Oxidant Stress in Atherothrombotic Disease
Patrono, C., & FitzGerald, G. A. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.2309 · Cited by 453
Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 456
Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439
Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C. H., Bolger, A. P., Sharma, R. K., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Urinary Albumin Excretion
Borch‐Johnsen, K., Feldt‐Rasmussen, B., Strandgaard, S., Schroll, M., & Jensen, J. S. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.8.1992 · Cited by 441
Lipoproteins, nutrition, and heart disease
Schaefer, E. J. (2002) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.2.191 · Cited by 436
Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
Yaffe, K. S., Barrett-Connor, E. L., Lin, F., & Grady, D. G. (2002) · Archives of Neurology · doi:10.1001/archneur.59.3.378 · Cited by 445
A novel anti-inflammatory role for simvastatin in inflammatory arthritis.
Leung, B. P., Sattar, N., Crilly, A., Prach, M., McCarey, D. W., Payne, H., Madhok, R., Campbell, C., Gracie, J. A., Liew, F. Y., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1524 · Cited by 434
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. G. (2006) · Circulation · doi:10.1161/circulationaha.106.655688 · Cited by 471
The ubiquitous role of nitric oxide in cardioprotection
Jones, S. P., & Bolli, R. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.09.011 · Cited by 434
Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin: The Cholesterol and Recurrent Events (CARE) Study
Plehn, J. F., Davis, B. R., Sacks, F. M., Rouleau, J. L., Pfeffer, M. A., Bernstein, V., Cuddy, T. E., Moyé, L. A., Piller, L. B., Rutherford, J., et al. (1999) · Circulation · doi:10.1161/01.cir.99.2.216 · Cited by 429
Bone Marrow–Derived Progenitor Cells Modulate Vascular Reendothelialization and Neointimal Formation
Werner, N., Priller, J., Laufs, U., Endres, M., Böhm, M., Dirnagl, U., & Nickenig, G. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000036417.43987.d8 · Cited by 433
Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Antonopoulos, A. S., Margaritis, M., Lee, R., Channon, K. M., & Antoniades, C. A. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504803 · Cited by 440
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial
Lewis, S. J., Moye, L. A., Sacks, F. M., Johnstone, D. E., Timmis, G., Mitchell, J., Limacher, M., Kell, S., Glasser, S. P., Grant, J., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-9-199811010-00002 · Cited by 427
Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
Fruchart, J.-C., Duriez, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00007 · Cited by 425
THE REGULATION AND PHARMACOLOGY OF ENDOTHELIAL NITRIC OXIDE SYNTHASE
Dudzinski, D. M., Igarashi, J., Greif, D. M., & Michel, T. M. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121844 · Cited by 425
Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study
Schatz, I. J., Masaki, K., Yano, K., Chen, R., Rodríguez, B. L., & Curb, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05553-2 · Cited by 425
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D. J., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 427
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
Bustos, C., Hernández-Presa, M. Á., Ortego, M., Tuñón, J., Ortega, L. M., Pérez, F., Díaz, C., Hernández, G., & Egido, J. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00487-2 · Cited by 417
Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000100688.17280.e6 · Cited by 424
Guidelines for the management of chronic kidney disease
Levin, A., Hemmelgarn, B. R., Culleton, B. F., Tobe, S. W., McFarlane, P., Ruzicka, M., Burns, K. D., Manns, B., White, C., Madore, F., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080351 · Cited by 428
Estrogen replacement therapy, atherosclerosis, and vascular function
Mikkola, T. S. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00466-7 · Cited by 423
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
Ballantyne, C. M., Olsson, A. G., Cook, T. J., Mercuri, M. F., Pedersen, T. R., & Kjekshus, J. (2001) · Circulation · doi:10.1161/hc5001.100624 · Cited by 416
Atherosclerotic Vascular Disease Conference
Faxon, D. P., Fuster, V., Libby, P., Beckman, J. A., Hiatt, W. R., Thompson, R. W., Topper, J. N., Annex, B. H., Rundback, J. H., Fabunmi, R. P., et al. (2004) · Circulation · doi:10.1161/01.cir.0000128520.37674.ef · Cited by 421
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol: A Randomized Controlled Trial
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410
Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
(2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.054 · Cited by 418
Dietary pattern and 20 year mortality in elderly men in Finland, Italy, and the Netherlands: longitudinal cohort study
Huijbregts, P., Feskens, E. J. M., Räsänen, L., Fidanza, F., Nissinen, A. M., Menotti, A., & Kromhout, D. (1997) · BMJ · doi:10.1136/bmj.315.7099.13 · Cited by 415
HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia
Weber, C., Erl, W., Weber, K. S. C., & Weber, P. C. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00324-0 · Cited by 409
Treatment of Asymptomatic Adults With Elevated Coronary Calcium Scores With Atorvastatin, Vitamin C, and Vitamin E
Arad, Y., Spadaro, L. A., Roth, M., Newstein, D., & Guerci, A. D. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.089 · Cited by 414
Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 440
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 409
Multifactorial causation of obesity: implications for prevention
Grundy, S. M. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.3.563s · Cited by 403
Small LDL, Atherogenic Dyslipidemia, and the Metabolic Syndrome
Grundy, S. M. (1997) · Circulation · doi:10.1161/01.cir.95.1.1 · Cited by 402
Infection and Inflammation‐Induced Proatherogenic Changes of Lipoproteins
Khovidhunkit, W., Memon, R. A., Feingold, K. R., & Grünfeld, C. (2000) · The Journal of Infectious Diseases · doi:10.1086/315611 · Cited by 403
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations
Grundy, S. M., Pasternak, R. C., Greenland, P., Smith, S. C., & Fuster, V. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00387-3 · Cited by 403
Statin-Sensitive Dysregulated AT1 Receptor Function and Density in Hypercholesterolemic Men
Nickenig, G., Bäumer, A. T., Temur, Y., Kebben, D., Jockenhövel, F., & Böhm, M. (1999) · Circulation · doi:10.1161/01.cir.100.21.2131 · Cited by 394
Comparison of statins in hypertriglyceridemia
Stein, E. A., Lane, M., & Laskarzewski, P. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00041-1 · Cited by 386
Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management
(1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00200-7 · Cited by 396
Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project
Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., et al. (2000) · Circulation · doi:10.1161/01.cir.102.16.1893 · Cited by 388
Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes
Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1151 · Cited by 390
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
US Preventive Services Task Force, Mangione, C. M., Barry, M. J., Nicholson, W. K., Cabana, M. D., Chelmow, D. P., Coker, T. R., Davis, E. M., Donahue, K. E., Jaén, C. R., et al. (2022) · JAMA · doi:10.1001/jama.2022.13044 · Cited by 398
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Wilke, R. A., Lin, D. W., Roden, D. M., Watkins, P. B., Flockhart, D. A., Zineh, I., Giacomini, K. M., & Krauss, R. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2423 · Cited by 400
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture
Guijarro, C., Blanco‐Colio, L. M., Ortego, M., Alonso, C., Ortíz, A., Plaza, J. J. G., Dı́az-Jullien, C., Hernández, G., & Egido, J. (1998) · Circulation Research · doi:10.1161/01.res.83.5.490 · Cited by 390
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease
Kjekshus, J., Pedersen, T. R., Olsson, A. G., Færgeman, O., & Pyörälä, K. (1997) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(97)90022-1 · Cited by 386
Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study
Asakura, M., Ueda, Y., Yamaguchi, O., Adachi, T., Hirayama, A., Hori, M., & Kodama, K. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01135-4 · Cited by 383
Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22.
Tomás Pantoja, C., & Luz María Letelier, S. (2003) · Revista médica de Chile · doi:10.4067/s0034-98872003001000017 · Cited by 386
Number needed to screen: development of a statistic for disease screening
Rembold, C. M. (1998) · BMJ · doi:10.1136/bmj.317.7154.307 · Cited by 385
Statins Alter Smooth Muscle Cell Accumulation and Collagen Content in Established Atheroma of Watanabe Heritable Hyperlipidemic Rabbits
Fukumoto, Y., Libby, P., Aikawa, E. R., Hill, C. C., Enomoto, M., Hirouchi, Y., Shiomi, M., & Aikawa, M. (2001) · Circulation · doi:10.1161/01.cir.103.7.993 · Cited by 383
3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27
Laufs, U., Marra, D. E., Node, K., & Liao, J. K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21926 · Cited by 381
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease
Tonelli, M. A., Isles, C., Curhan, G. C., Tonkin, A. M., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C. D., Cobbe, S. M., Simes, J. R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143892.84582.60 · Cited by 374
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA · doi:10.1001/jama.1996.03530250059028 · Cited by 378
Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction.
Sharir, T., Germano, G., Kang, X., Lewin, H. C., Miranda, R., Cohen, I., Agafitei, R. D., Friedman, J. D., & Berman, D. S. (2001) · PubMed · Cited by 375
Inhibition of Rho Kinase (ROCK) Leads to Increased Cerebral Blood Flow and Stroke Protection
Rikitake, Y., Kim, H.-H., Huang, Z., Seto, M., Yano, K., Asano, T., Moskowitz, M. A., & Liao, J. K. (2005) · Stroke · doi:10.1161/01.str.0000181077.84981.11 · Cited by 375
Elevated Alanine Aminotransferase Predicts New-Onset Type 2 Diabetes Independently of Classical Risk Factors, Metabolic Syndrome, and C-Reactive Protein in the West of Scotland Coronary Prevention Study
Sattar, N. A., Scherbakova, O., Ford, I., O’Reilly, D. S. J., Stanley, A. J., Forrest, E. H., Macfarlane, P. W., Packard, C. J., Cobbe, S. M., & Shepherd, J. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2855 · Cited by 376
Novel Inflammatory Markers of Coronary Risk
Libby, P., & Ridker, P. M. (1999) · Circulation · doi:10.1161/01.cir.100.11.1148 · Cited by 375
Primary Prevention of Ischemic Stroke
Goldstein, L. B., Adams, R. J., Becker, K. J., Furberg, C. D., Gorelick, P. B., Hádemenos, G. J., Hill, M., Howard, G., Howard, V. J., Jacobs, B. S., et al. (2001) · Circulation · doi:10.1161/01.cir.103.1.163 · Cited by 374
Relationship Between Plasma LDL Concentrations During Treatment With Pravastatin and Recurrent Coronary Events in the Cholesterol and Recurrent Events Trial
Sacks, F. M., Moyé, L. A., Davis, B. R., Cole, T. G., Rouleau, J. L., Nash, D. T., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.97.15.1446 · Cited by 371
Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology?
Ebrahim, S., & Davey Smith, G. (2008) · Human Genetics · doi:10.1007/s00439-007-0448-6 · Cited by 410
Phytochemicals for Health, the Role of Pulses
Rochfort, S. J., & Panozzo, J. (2007) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf071704w · Cited by 383
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Use of Intravascular Ultrasound to Compare Effects of Different Strategies of Lipid-Lowering Therapy on Plaque Volume and Composition in Patients With Coronary Artery Disease
Schartl, M., Bocksch, W., Koschyk, D. H., Voelker, W., Karsch, K. R., Kreuzer, J., Hausmann, D., Beckmann, S., Gross, M. C., & for the German Atorvastatin Intravascular Ultrasound Study Investigators (GAIN) (2001) · Circulation · doi:10.1161/hc2901.093188 · Cited by 364
Severity of Coronary Artery Calcification by Electron Beam Computed Tomography Predicts Silent Myocardial Ischemia
He, Z., Hedrick, T. D., Pratt, C. M., Verani, M. S., Aquino, V., Roberts, R., & Mahmarian, J. J. (2000) · Circulation · doi:10.1161/01.cir.101.3.244 · Cited by 357
Our Reviewers
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 355
Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B
Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J. Q., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 357
Escitalopram and Problem-Solving Therapy for Prevention of Poststroke Depression
Robinson, R. G., Jorge, R. E., Moser, D. J., Ación, L., Solodkin, A., Small, S. L., Fonzetti, P., Hegel, M. T., & Arndt, S. V. (2008) · JAMA · doi:10.1001/jama.299.20.2391 · Cited by 360
Nutrigenomics and nutrigenetics: the emerging faces of nutrition
Mutch, D. M., Wahli, W., & Williamson, G. (2005) · The FASEB Journal · doi:10.1096/fj.05-3911rev · Cited by 359
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1716 · Cited by 351
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352
Immunosuppressive drugs: the first 50 years and a glance forward
ALLISON, A. C. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00186-7 · Cited by 351
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials
Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340
Guidelines for the management of arterial hypertension
van de Borne, P. (2014) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · doi:10.2143/ac.69.1.3011345 · Cited by 349
In Vivo Formation of 8-Epi-Prostaglandin F2αIs Increased in Hypercholesterolemia
Davı̀, G., Alessandrini, P., Mezzetti, A., Minotti, G., Bucciarelli, T., Costantini, F., Cipollone, F., Bon, G. B., Ciabattoni, G., & Patrono, C. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.11.3230 · Cited by 350
Cardiac cachexia: A systematic overview
von Haehling, S., Lainščak, M., Springer, J., & Anker, S. D. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 356
Primary Prevention of Cardiovascular Diseases With Statin Therapy
Thavendiranathan, P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2307 · Cited by 349
Breast Cancer Growth Prevention by Statins
Campbell, M. J., Esserman, L. J., Zhou, Y., Shoemaker, M., Lobo, M., Borman, E., Baehner, F. L., Kumar, A. S., Adduci, K., Marx, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4061 · Cited by 353

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks